Listed

Utah Medical Products Inc

UTMDNasdaqCIK 706698HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$8.5mRevenue, Q2 FY2026, three months to 2026-06-30$8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 12, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$8.5mRevenue, Q2 FY2026, three months to 2026-06-30$8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure−14.3% on a year earlier
  • Gross margin55.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $4.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure−0.4 pts on a year earlier
  • Operating margin31.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure−1.1 pts on a year earlier
  • Net margin31.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $2.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure+0.9 pts on a year earlier
  • Diluted EPS$0.84Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure−10.6% on a year earlier
  • Free cash flow$1.2mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Capital expenditure: $134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Report this figure−55.7% on a year earlier

Last eight quarters

Full statements
Revenue$8.5mGross margin 55.8%
Diluted EPS$0.84, Q2 FY2026
Free cash flow$1.2m, Q2 FY2026
Utah Medical Products Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m10.0Revenue, Q3 FY2024, three months to 2024-09-30$10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure9.2Revenue, Q4 FY2024, three months to 2024-12-31$9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure9.7Revenue, Q1 FY2025, three months to 2025-03-31$9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure10.0Revenue, Q2 FY2025, three months to 2025-06-30$10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure9.8Revenue, Q3 FY2025, three months to 2025-09-30$9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure9.0Revenue, Q4 FY2025, three months to 2025-12-31$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure8.7Revenue, Q1 FY2026, three months to 2026-03-31$8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure8.5Revenue, Q2 FY2026, three months to 2026-06-30$8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure
Gross margin%58.0%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $5.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure58.1%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $5.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure57.0%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $5.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure56.2%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $5.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure57.1%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $5.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure58.2%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $5.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure60.6%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $5.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Revenue: $8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure55.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $4.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure
Operating margin%33.4%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001096906-25-001839.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure32.0%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure32.5%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure32.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure26.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001096906-25-001839.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure27.0%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure29.4%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Revenue: $8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure31.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure
Net margin%35.6%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $3.6m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure31.7%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $2.9m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure31.3%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $3.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure30.6%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $3.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure26.8%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $2.6m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure28.4%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $2.6m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure29.9%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $2.6m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure31.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $2.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure
Diluted EPS$ per share1.03Diluted EPS, Q3 FY2024, three months to 2024-09-30$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure0.86Diluted EPS, Q4 FY2024, three months to 2024-12-31$0.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure0.92Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure0.94Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure0.82Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure0.80Diluted EPS, Q4 FY2025, three months to 2025-12-31$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure0.82Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure0.84Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001096906-26-001210.Report this figure
Free cash flow$m3.8Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001096906-25-001839. Derived: 9-month figure less the 6-month figure.Capital expenditure: $89.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001096906-25-001839. Derived: 9-month figure less the 6-month figure.Report this figure2.9Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Capital expenditure: $9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Report this figure4.3Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Capital expenditure: $184.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure2.8Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Capital expenditure: $51.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Report this figure3.9Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001096906-25-001839. Derived: 9-month figure less the 6-month figure.Capital expenditure: $27.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001096906-25-001839. Derived: 9-month figure less the 6-month figure.Report this figure3.4Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Capital expenditure: $109.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001096906-26-000395. Derived: 12-month figure less the 9-month figure.Report this figure3.0Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Capital expenditure: $130.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001096906-26-000767.Report this figure1.2Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Capital expenditure: $134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001096906-26-001210. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$38.5mGross margin 57.1%
Diluted EPS$3.48, FY2025
Free cash flow$14.3m, FY2025
Utah Medical Products Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m49.1Revenue, FY2021, twelve months to 2021-12-31$49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure52.3Revenue, FY2022, twelve months to 2022-12-31$52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure50.2Revenue, FY2023, twelve months to 2023-12-31$50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure40.9Revenue, FY2024, twelve months to 2024-12-31$40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure38.5Revenue, FY2025, twelve months to 2025-12-31$38.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure
Gross margin%63.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $30.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-26, accession 0001811884-24-000009.Revenue: $49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure61.6%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $32.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-26, accession 0001096906-25-000308.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure59.8%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $30.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure59.0%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $24.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure57.1%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $22.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $38.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure
Operating margin%38.5%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-26, accession 0001811884-24-000009.Revenue: $49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure37.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $19.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-26, accession 0001096906-25-000308.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure33.4%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $16.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure33.2%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $13.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure29.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $38.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure
Net margin%30.1%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $14.8m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2024-03-26, accession 0001811884-24-000009.Revenue: $49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure31.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $16.5m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2025-03-26, accession 0001096906-25-000308.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure33.1%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $16.6m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure33.9%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $13.9m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure29.3%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $11.3m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-27, accession 0001096906-26-000395.Revenue: $38.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure
Diluted EPS$ per share4.04Diluted EPS, FY2021, twelve months to 2021-12-31$4.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure4.52Diluted EPS, FY2022, twelve months to 2022-12-31$4.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure4.57Diluted EPS, FY2023, twelve months to 2023-12-31$4.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure3.96Diluted EPS, FY2024, twelve months to 2024-12-31$3.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure3.48Diluted EPS, FY2025, twelve months to 2025-12-31$3.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure
Free cash flow$m20.7Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $21.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-26, accession 0001811884-24-000009.Capital expenditure: $552.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-26, accession 0001811884-24-000009.Report this figure20.3Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $21.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-26, accession 0001096906-25-000308.Capital expenditure: $809.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-26, accession 0001096906-25-000308.Report this figure21.6Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $22.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001096906-26-000395.Capital expenditure: $639.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure14.6Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001096906-26-000395.Capital expenditure: $230.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure14.3Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $14.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001096906-26-000395.Capital expenditure: $371.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001096906-26-000395.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $66.8kSales $0
Utah Medical Products Inc, open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-29Cornwell Kevin LChairman, CEO, Director, Officer Purchase1,000$66.75$66.8kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Utah Medical Products Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BRANDES INVESTMENT PARTNERS, LP2026-06-30$32.8m475,158Added+25,879
BlackRock, Inc.2026-06-30$14.1m203,690Added+16,041
DIMENSIONAL FUND ADVISORS LP2026-06-30$13.7m198,817Added+909
RENAISSANCE TECHNOLOGIES LLC2026-06-30$12.1m175,814Reduced−8,300
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$9.3m134,535Reduced−4,025
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$7.5m108,048Reduced−12,049
Minerva Advisors LLC2026-06-30$6.5m93,615Unchanged
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC2026-06-30$5.9m85,231Reduced−3,900
RICE HALL JAMES & ASSOCIATES, LLC2026-06-30$4.9m71,363Added+3,481
MORGAN STANLEY2026-06-30$4.8m69,671Added+20,870

Recent filings

All 542 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Utah Medical Products Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2215:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001096906-26-001602
2026-08-3113:33 ET8-K7.01 Regulation FD disclosure0001096906-26-001326
2026-08-1213:57 ET10-QQuarterly reportPeriod 2026-06-300001096906-26-001210
2026-07-2315:13 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001096906-26-001112
2026-05-1215:52 ET10-QQuarterly reportPeriod 2026-03-310001096906-26-000767
2026-05-0415:09 ET8-K5.07 Shareholder vote results0001096906-26-000685
2026-04-2315:49 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001096906-26-000602
2026-04-0216:59 ETDEF 14AProxy statementPeriod 2026-04-020001096906-26-000477
2026-03-2717:23 ET10-KAnnual reportPeriod 2025-12-310001096906-26-000395
2026-01-2915:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001096906-26-000161

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
706698
Tickers
UTMD
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
UT
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:47 ET. Listed shows no prices and gives no investment advice.